Description

Lead Optimisation - CRT Discovery Laboratories Project. Small molecule inhibitors of Autotaxin (ATX) have been discovered using an HTS approach and are currently undergoing lead optimisation. ATX cleaves choline from lysophosphatidylcholine (LPC) forming lysophosphatidic acid (LPA), a potent mitogen that has been implicated in the pathophysiology of cancer. ATX has been demonstrated to increase cell motility, neovascularization, proliferation and aggressiveness of tumours. It is upregulated in numerous tumour lineages (breast, glioblastoma, ovarian and prostate cancer).

Download the PDF of Inhibitors of Autotaxin

For more information please contact

Dr Theo Balasas

+44 (0) 20 3469 6300 .(JavaScript must be enabled to view this email address)